{"title":"Model-Based Economic Evaluations of Interleukin Pathway Inhibitors for Moderate-to-Severe Plaque Psoriasis: A Systematic Review of Model Structures, Assumptions, and Methodological Quality.","authors":"Zhi Wang, Zixin Zhang, Pingyu Chen","doi":"10.1007/s40258-026-01087-7","DOIUrl":"https://doi.org/10.1007/s40258-026-01087-7","url":null,"abstract":"<p><strong>Objectives: </strong>To systematically review model-based economic evaluations of interleukin pathway inhibitors for moderate-to-severe plaque psoriasis, with a focus on model structures, key assumptions, parameter sources, economic conclusions, methodological rigor, and reporting completeness.</p><p><strong>Methods: </strong>PubMed/MEDLINE, Embase, Web of Science, and the Cochrane Library were systematically searched from database inception through July 10, 2026, for full model-based economic evaluations in adults with moderate-to-severe plaque psoriasis in which at least one evaluated strategy included an interleukin (IL)-12/23, IL-17, or IL-23 inhibitor. Model architecture, health states, treatment sequences, sources of key parameters, and approaches to uncertainty were extracted a priori, and methodological features were compared through narrative synthesis. Methodological quality and reporting completeness were appraised using the Philips checklist and the Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022), respectively. Economic findings were synthesized separately for QALY-based cost-utility analyses and Psoriasis Area and Severity Index (PASI) response-based cost-effectiveness analyses.</p><p><strong>Results: </strong>Twenty-six economic evaluations met the inclusion criteria. Thirteen used Markov or state-transition models, five used decision tree-Markov hybrids, two used decision trees, four used cost-effectiveness models without a stated formal architecture, and two used patient-level or other simulation models; 14 explicitly modeled multi-line treatment sequences. Twenty-four evaluations used evidence from randomized controlled trials as effectiveness inputs, and 19 incorporated network meta-analysis or mixed-treatment comparison estimates. Twenty-one conducted formal deterministic sensitivity analyses, with one additional evaluation reporting a limited one-way analysis; 20 conducted probabilistic sensitivity analyses, and 16 reported cost-effectiveness acceptability curves. Only four studies explicitly described tests of model logic, and none systematically compared alternative model structures; subsequent-line effectiveness and patient heterogeneity were also inconsistently addressed. Economically, 16 evaluations were QALY-based cost-utility analyses and 10 were PASI response-based cost-effectiveness analyses. No drug or treatment sequence was consistently optimal across countries; conclusions varied primarily with comparator choice, drug prices, willingness-to-pay thresholds, short-term response rates, and sequencing assumptions.</p><p><strong>Conclusions: </strong>Existing models increasingly represent long-term, multi-line treatment pathways, but their treatment of prior treatment history, subsequent-line effectiveness and discontinuation, structural uncertainty, and model validation remains inadequate. Future evaluations should incorporate previous biologic exposure, long-term drug survival","PeriodicalId":8065,"journal":{"name":"Applied Health Economics and Health Policy","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149401390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Md Zahid Hasan, Edward J D Webb, Zahidul Quayyum, Tim Ensor
{"title":"Preferences for Primary Healthcare Providers Among Urban Slum Dwellers of Dhaka City in Bangladesh: A Discrete Choice Experiment.","authors":"Md Zahid Hasan, Edward J D Webb, Zahidul Quayyum, Tim Ensor","doi":"10.1007/s40258-026-01076-w","DOIUrl":"https://doi.org/10.1007/s40258-026-01076-w","url":null,"abstract":"<p><strong>Background and objective: </strong>Strengthening the urban primary healthcare system is essential for delivering need-based services to the rapidly growing low-income urban population in Bangladesh. This study examined the preferences of slum dwellers for primary healthcare providers under hypothetical minor and major illness conditions.</p><p><strong>Methods: </strong>A discrete choice experiment was conducted among 304 slum dwellers in Dhaka, Bangladesh, in January-February 2024. Six final attributes (time to reach healthcare centre, waiting time to see a provider, recommendation from neighbours/relatives, type of healthcare provider, consultation fee and medicine expenditure) were identified through a systematic review, focus group discussions and key informant interviews, and finalised through a community ranking exercise and expert consultation. A Bayesian D-efficient design was used to construct choice sets, each presenting two hypothetical primary healthcare providers and an opt-out option; respondents completed each choice set for minor and major illnesses. Data were analysed using mixed logit models (in preference and willingness-to-pay space), relative importance analysis and latent class analysis.</p><p><strong>Results: </strong>Consultation fee had the highest relative importance for minor illness and type of healthcare provider for major illness. An MBBS/qualified doctor for minor illness and a senior/experienced doctor for major illness were strongly preferred over non-qualified providers. Utility decreased significantly with longer travel time (60 min) and waiting time (30 min), and higher consultation fees (p < 0.001). Compared with no recommendation, a negative recommendation significantly reduced utility for major illness, and a positive recommendation significantly increased utility for minor illness. Free medicines and a 50% discount on medicines significantly increased utility relative to no discount in both conditions (p ≤ 0.004), with higher utility for free medicines.</p><p><strong>Conclusions: </strong>Consultation fee was the most important attribute for minor illness and provider type for major illness; respondents also valued qualified providers, shorter travel and waiting times and free or discounted medicines. Deploying qualified doctors in accessible community facilities, reducing consultation fees and subsidising medicines may improve the uptake of primary healthcare among urban slum dwellers in Bangladesh. These findings can inform patient-centred primary healthcare policy for low-income urban populations.</p>","PeriodicalId":8065,"journal":{"name":"Applied Health Economics and Health Policy","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149261181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Financing High-Cost Gene Therapy Under Clinical Uncertainty: Assessing Budget Impact of Reimbursement Models for Hemgenix<sup>®</sup> in Hemophilia B in Sweden.","authors":"Shalini Padhy, Pia Johansson","doi":"10.1007/s40258-026-01077-9","DOIUrl":"https://doi.org/10.1007/s40258-026-01077-9","url":null,"abstract":"<p><strong>Aim: </strong>Advanced therapy medicinal products, a European Union regulatory category encompassing gene-, cell-, and tissue-based medicines, challenge conventional reimbursement frameworks, particularly when a single administration entails high upfront costs and long-term effectiveness uncertainty. This study assessed the treatment-cost budget impact under three reimbursement models for etranacogene dezaparvovec (Hemgenix<sup>®</sup>) in hemophilia B within the high-income, decentralized, tax-financed healthcare system of Sweden.</p><p><strong>Methods: </strong>Using a decision-support framework, an outcome-based annuity model was identified as a relevant reimbursement strategy for Hemgenix<sup>®</sup>. A cohort Markov model simulated per-patient treatment costs for payers for Hemgenix<sup>®</sup> and the comparator factor IX prophylaxis over 5, 10, and 15 years for a hypothetical cohort of adults with hemophilia B. Three reimbursement strategies-full upfront, 30% reduced upfront, and outcome-based annuity reimbursement-were compared with costs for factor IX prophylaxis under three scenarios: short-term trial outcomes, a full response, and partial response (10% annual failure rate). One-way sensitivity analyses examined varying treatment durability, cost of Hemgenix<sup>®</sup> and factor IX prophylaxis, mortality rates, and extended time horizon.</p><p><strong>Results: </strong>Hemgenix<sup>®</sup> was more expensive than standard prophylaxis in the first 10 years under all scenarios and reimbursement strategies in Sweden. However, at 15 years, the 30% reduced upfront model and outcome-based annuity model incur lower treatment costs than prophylaxis in selected scenarios. Under sustained full treatment response, the reduced upfront reimbursement model showed the lowest treatment costs, while the outcome-based annuity model resulted in lower costs under partial and diminishing treatment effectiveness.</p><p><strong>Conclusion: </strong>In this Swedish, budget-impact analysis, the treatment cost of Hemgenix<sup>®</sup> depended strongly on assumptions about long-term durability and reimbursement design. The study shows outcome-based annuity reimbursements reduce payers' treatment-cost exposure under long-term uncertainty, whereas upfront reimbursement minimized the cost of Hemgenix<sup>®</sup> treatment only with sustained response. However, this cost advantage under partial response was not maintained after applying 3% annual discounting.</p>","PeriodicalId":8065,"journal":{"name":"Applied Health Economics and Health Policy","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149261231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nirmali Sivapragasam, David Brain, Gayani Amarasinghe, Sameera Senanayake, Sanjeewa Kularatna, Nicole M White
{"title":"Variation in Health State Utility Values Across Preference-Based Instruments: A Systematic Review and Meta-analysis of Behavioural Risk Factors.","authors":"Nirmali Sivapragasam, David Brain, Gayani Amarasinghe, Sameera Senanayake, Sanjeewa Kularatna, Nicole M White","doi":"10.1007/s40258-026-01083-x","DOIUrl":"https://doi.org/10.1007/s40258-026-01083-x","url":null,"abstract":"<p><strong>Background: </strong>Health economic evaluations require health state utility values (HSUVs) to estimate quality-adjusted life years (QALYs). However, HSUVs derived from different preference-based instruments, valuation methods and value sets may not be directly comparable, which can affect interpretation of economic evaluations. Although reference cases, such as that of the National Institute for Health and Care Excellence (NICE), specify a preferred instrument, such as the EQ-5D, alternative measures are frequently used in practice. Using behavioural risk factors as an applied case, this study examined variation in HSUVs across instruments and synthesised utility estimates for body mass index (BMI) and smoking categories.</p><p><strong>Methods: </strong>A systematic review of population-based observational studies published between 2009 and 2024 was conducted across PubMed, Embase, Web of Science and EconLit. Random-effects meta-analyses were used to estimate pooled HSUVs by instrument type and risk factor category. Mixed-effects meta-regression models explored associations between behavioural risk factors, health-related quality of life (HRQoL) instrument type and variation in HSUVs while accounting for clustering of multiple estimates within studies. Preference-based instruments included the EQ-5D, Health Utilities Index (HUI), Short Form 6-Dimension (SF-6D) and Quality of Well-Being (QWB) scale. Given the anticipated heterogeneity across studies, pooled estimates were used to describe variation in reported HSUVs.</p><p><strong>Results: </strong>Forty-four articles were included, contributing 186 utility estimates across five instrument categories. Substantial variation in HSUVs was observed across instruments with consistent patterns evident across BMI and smoking categories. Relative to the EQ-5D-3L, the HUI, SF-6D and QWB yielded systematically lower utility values. The EQ-5D-5L yielded higher values in the BMI model, but the corresponding estimate in the smoking model was not statistically significant. Variation associated with instrument categories, which may also reflect related valuation and derivation differences, was comparable, and in some cases greater than, differences observed across BMI and smoking categories, although substantial between-study heterogeneity remained (I<sup>2</sup> > 90%). Lower HSUVs were observed among individuals who were underweight, overweight or obese compared with those of normal weight and among former and current smokers compared with never smokers. Former smokers reported lower values than current smokers, consistent with selection effects. Alcohol use was reported in too few studies to support reliable instrument-stratified pooling, and reported values overlapped substantially across drinking categories.</p><p><strong>Conclusions: </strong>Reported HSUVs varied systematically across preference-based instruments, with differences comparable to, and in some cases exceeding, those associated w","PeriodicalId":8065,"journal":{"name":"Applied Health Economics and Health Policy","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149261169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mattia Barsanti, Salvatore Tallarico, Marco Praticò, Luisa Pellegrini, Riccardo Dulmin, Giandomenico Mastroeni, Simone Lazzini, Maria Rita Romeo
{"title":"A Post-market Decision-Making Framework for Medical Devices in Hospital Settings: the THE Mini-HTA Tool.","authors":"Mattia Barsanti, Salvatore Tallarico, Marco Praticò, Luisa Pellegrini, Riccardo Dulmin, Giandomenico Mastroeni, Simone Lazzini, Maria Rita Romeo","doi":"10.1007/s40258-026-01082-y","DOIUrl":"https://doi.org/10.1007/s40258-026-01082-y","url":null,"abstract":"<p><strong>Background: </strong>Hospital adoption of medical devices requires structured governance mechanisms capable of integrating clinical, economic, organizational, and patient-centered dimensions. However, hospital-based health technology assessment processes remain heterogeneous and often lack standardized yet adaptable frameworks.</p><p><strong>Methods: </strong>We present the THE Mini-HTA ('THE' is the acronym for the Tuscany Health Ecosystem research project within the PNRR-Piano Nazionale di Ripresa e Resilienza (National Recovery and Resilience Plan)-as part of which the tool was developed), a hospital-oriented decision-support tool for post-market medical device evaluation. The framework combines a standardized set of ten dimensions and 39 criteria, derived from the EUnetHTA<sup>®</sup> Core Model and expanded to include new criteria, with a structured governance architecture that differentiates process coordination from domain-specific expert evaluation. The decision model is based on PROMETHEE, a non-compensatory multi-criteria decision analysis approach, aimed at preventing inappropriate compensation between critical criteria. An automated platform supports the full evaluation workflow, generating individual and collective rankings and enabling sensitivity analyses. The tool was implemented for assessing two implantable cardioverter defibrillators in an Italian tertiary care hospital highly specialized in cardiology and cardiac surgery.</p><p><strong>Results: </strong>The real-world application provides initial empirical evidence of the tool's operational feasibility in a real decision-making context, involving domain experts with different expertise, a clinically relevant comparative problem, which represent the conditions typically encountered in hospital-based post-market medical device evaluation. The outputs of the tool can support final deliberation and reporting by clarifying where the comparative advantages originated and the magnitude of residual differences between alternatives, while reducing perceptions of a \"black-box\" decision process.</p><p><strong>Conclusions: </strong>The THE Mini-HTA provides a scientifically grounded and operationally implementable framework to strengthen hospital-level health technology assessment. Future research should validate the tool across a broader range of medical devices and healthcare settings, and examine its integration into routine health technology assessment workflows.</p>","PeriodicalId":8065,"journal":{"name":"Applied Health Economics and Health Policy","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149261200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Persefoni Kritikou, Gregory F Guzauskas, Constantinos Papadopoulos, Sophia Xirou, George Papadimas
{"title":"Home-Based Versus Hospital-Based Administration of Enzyme Replacement Therapy for Late-Onset Pompe Disease in Greece: A Cost-Utility and Budget Impact Analysis.","authors":"Persefoni Kritikou, Gregory F Guzauskas, Constantinos Papadopoulos, Sophia Xirou, George Papadimas","doi":"10.1007/s40258-026-01084-w","DOIUrl":"https://doi.org/10.1007/s40258-026-01084-w","url":null,"abstract":"<p><strong>Objectives: </strong>Enzyme replacement therapy (ERT) for late-onset Pompe disease (LOPD) requires lifelong biweekly infusions, typically delivered in hospital settings. Home-based administration has been associated with reduced treatment burden and pressure on hospital infusion services. This study evaluated the cost-effectiveness and budget impact of home-based versus hospital-based ERT administration for adults with LOPD in Greece.</p><p><strong>Methods: </strong>A decision-analytic model was developed to conduct a cost-utility analysis (CUA) and a budget impact analysis (BIA) from the perspective of the Greek public healthcare system. The CUA adopted a 50-year horizon and estimated costs and quality-adjusted life-years (QALYs) associated with home- and hospital-based ERT administration. Clinical and cost inputs were derived from published literature, Greek sources, and expert consultation. Cost categories included drug cost, infusion administration, management of severe infusion-associated reactions (IARs), and one-off home-infusion nurse training. The BIA estimated the financial consequences of gradually introducing home-based ERT for the national cohort of treated patients over a 5-year horizon.</p><p><strong>Results: </strong>In the base-case CUA, home-based ERT administration was associated with lower costs (€6,999,500 vs €7,150,725) and modestly higher QALYs (14.342 vs 14.235 QALYs) than hospital-based administration. Cost savings were driven primarily by lower administration costs, while QALY gains reflected avoidance of process-related disutility associated with hospital attendance. The BIA projected cumulative 5-year savings of €263,667 and 1174 fewer hospital infusion visits under the base-case adoption trajectory. Scenario analyses showed that the magnitude of cost savings was sensitive to the valuation of hospital administration, while removal of hospital process-related disutility reduced the incremental QALY gain to a negligible level; the direction of the cost findings remained unchanged across the scenarios evaluated.</p><p><strong>Conclusions: </strong>Home-based ERT administration for adults with LOPD in Greece was projected to reduce healthcare costs while generating modest health benefits, compared to hospital-based administration, potentially improving healthcare system efficiency.</p>","PeriodicalId":8065,"journal":{"name":"Applied Health Economics and Health Policy","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149261252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Christel Castelli, Coralie Delettrez, Amandine Coffy, Svletana Artemova, Julie Bulsei, Katia Charriere, Sandra David-Tchouda, Benoît Dervaux, Vera Georgescu, Alicia Le Bras, Aubane L'hospital, Sandrine Loubière, Jennifer Margier, Arnaud Pagès, Hassan Serrier, Anne-Laure Soilly, Marie Viprey, Michaël Mounié, Nadège Costa
{"title":"The Challenge of Unit Cost Harmonisation: A French National Reference Unit Cost for Healthcare Services (the MOVIE Project).","authors":"Christel Castelli, Coralie Delettrez, Amandine Coffy, Svletana Artemova, Julie Bulsei, Katia Charriere, Sandra David-Tchouda, Benoît Dervaux, Vera Georgescu, Alicia Le Bras, Aubane L'hospital, Sandrine Loubière, Jennifer Margier, Arnaud Pagès, Hassan Serrier, Anne-Laure Soilly, Marie Viprey, Michaël Mounié, Nadège Costa","doi":"10.1007/s40258-026-01079-7","DOIUrl":"https://doi.org/10.1007/s40258-026-01079-7","url":null,"abstract":"<p><strong>Objective: </strong>The lack of standardised unit cost data is a major barrier to the quality and comparability of health economic evaluations in France. Although such evaluations are often required for reimbursement decisions, no national reference cost framework existed outside the hospital sector. The MOVIE project fills this gap by developing the first French reference unit cost framework for 22 healthcare services, using 2021 data from a representative sample of the National Health Data System.</p><p><strong>Methods: </strong>Total billed amounts, social health insurance reimbursements, and patient out-of-pocket payments were estimated, in line with the collective perspective recommended by French authorities. The methodology was structured into three steps and was repeated for each of the 22 healthcare services. Step 1 consisted of a comprehensive literature review. Step 2 consisted of developing and executing the data query plan using the 2021 ESND database and then defining the statistical unit. Step 3 aimed to verify the consistency of the database with official statistics, estimates derived from the 2% sample that were extrapolated to the national level and compared with annually published macro-level data from official institutions collected in Step 1.</p><p><strong>Results: </strong>In 2021, the mean consultation cost was estimated at €39.8 (SD €12.6) for General Practitioners (GPs) and €66.1 (SD €37.1) for specialist physicians. Results show wide variation in unit costs across services, with low variability for allied health care and GP visits, and high variability and strong right-skewness for services such as inpatient care, chemotherapy, and dental care. Mean consultation costs were higher than commonly used tariffs, reflecting additional fees and incentives.</p><p><strong>Conclusion: </strong>Overall, this framework improves quality and comparability of economic evaluations and supports better-informed healthcare decision-making in France.</p>","PeriodicalId":8065,"journal":{"name":"Applied Health Economics and Health Policy","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149206432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Emaediong I Akpanekpo, Georgina M Chambers, Lee Knight, Peter W Schofield, Tony Butler
{"title":"Cost Effectiveness of Sertraline for Preventing Domestic Violence Reoffending Among Highly Impulsive Violent Offenders in Australia: A Trial-Based Economic Evaluation.","authors":"Emaediong I Akpanekpo, Georgina M Chambers, Lee Knight, Peter W Schofield, Tony Butler","doi":"10.1007/s40258-026-01080-0","DOIUrl":"https://doi.org/10.1007/s40258-026-01080-0","url":null,"abstract":"<p><strong>Background: </strong>Domestic violence generates significant health and justice costs, yet there is little trial-based clinical or economic evidence on pharmacological interventions for high-risk offenders. We evaluated the cost effectiveness of sertraline for reducing domestic violence reoffending among men with serious violent offending histories and high impulsivity.</p><p><strong>Objective: </strong>The primary objective was to estimate the incremental cost per domestic violence reoffence prevented for sertraline compared with placebo from a government payer perspective over 24 months.</p><p><strong>Methods: </strong>We conducted a cost-effectiveness analysis alongside a 24-month, double-blind, randomised controlled trial in New South Wales, Australia, comparing sertraline (n = 319) with placebo (n = 311). Both randomised groups received identical clinical support. A prespecified non-randomised group (N-Rand; n = 166) included eligible men who did not proceed to randomisation. The primary economic outcome was incremental cost per domestic violence reoffence prevented from a government perspective. Uncertainty was characterised using a probabilistic sensitivity analysis.</p><p><strong>Results: </strong>Domestic violence reoffending was lower with sertraline than placebo (28.2% vs 35.9%; risk ratio 0.79, p = 0.039) and N-Rand (42.2%; risk ratio 0.67, p = 0.002). Relative to placebo, sertraline generated net savings of Australian dollars (A$) 4443 per participant (A$57,636 per domestic violence reoffence prevented), with criminal justice savings (A$4839) exceeding medication costs (A$396). Relative to N-Rand, net savings were A$3327 per participant (A$23,841 per domestic violence reoffence prevented). In priobabilistic sensitivity analysis, sertraline (compared to placebo) had a mean incremental cost of -A$4507 (95% uncertainty interval -A$9,433, A$249) and 0.077 domestic violence reoffences prevented (95% confidence interval 0.004, 0.149). Sertraline was dominant in 95.1% of simulations, and in 84.9% versus N-Rand.</p><p><strong>Conclusions: </strong>Allocation to sertraline was associated with lower government costs and fewer domestic violence reoffences than placebo among men with serious violent offending histories and high impulsivity. Each reoffence prevented represents a reduction in violence experienced by victims, partners and children. These findings support consideration of sertraline as an adjunct within intervention and diversion programmes for high-risk offenders, where clinically indicated.</p><p><strong>Clinical trial registration: </strong>Australian New Zealand Clinical Trials Registry Identifier: ACTRN12613000442707.</p>","PeriodicalId":8065,"journal":{"name":"Applied Health Economics and Health Policy","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149206476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Laura R Porterfield, H Shelton Brown, Dallin Swanson, Revathi Gnanasekaran, Patricia Rodriguez Espinosa, Xiaoying Yu, Elizabeth M Vaughan
{"title":"Cost-Effectiveness of Community Health Worker Interventions for Type 2 Diabetes Mellitus: A Systematic Review.","authors":"Laura R Porterfield, H Shelton Brown, Dallin Swanson, Revathi Gnanasekaran, Patricia Rodriguez Espinosa, Xiaoying Yu, Elizabeth M Vaughan","doi":"10.1007/s40258-026-01081-z","DOIUrl":"10.1007/s40258-026-01081-z","url":null,"abstract":"<p><strong>Background: </strong>Type 2 diabetes contributes substantially to healthcare costs, disability, and premature mortality worldwide. Although community health worker (CHW) interventions improve glycemic outcomes and address social determinants of health, current cost-effectiveness evidence has not been systematically synthesized. We reviewed the economic evidence for CHW interventions in type 2 diabetes management.</p><p><strong>Methods: </strong>We searched Ovid MEDLINE, Scopus, CINAHL, and ProQuest from inception through August 2025 for peer-reviewed primary studies evaluating economic outcomes of CHW interventions for adults with type 2 diabetes. We extracted data and assessed study quality. Owing to heterogeneity in design, cost reporting, and limited variance estimates, we conducted a narrative synthesis.</p><p><strong>Results: </strong>Of 753 records, 11 met inclusion criteria. All studies focused on low-income and/or ethnic minority populations. Ten reported program costs ($29-6235 per patient/year; 2025 USD). Nine reported incremental cost-effectiveness ratios. Two of three short-term studies (< 5 years) found interventions cost-effective; all six long-term studies (≥ 20 years) found the same.</p><p><strong>Conclusions: </strong>Available evidence suggests that CHW interventions are likely cost-effective for adults with T2D, particularly when evaluated over longer time horizons.</p><p><strong>Prospero registration: </strong>CRD420251101900. https://www.crd.york.ac.uk/PROSPERO/view/CRD420251101900 .</p>","PeriodicalId":8065,"journal":{"name":"Applied Health Economics and Health Policy","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149190871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ureni Halahakone, Sameera Senanayake, Victoria McCreanor, William Parsonage, David Brain
{"title":"Cost-Effectiveness of Annual Atrial Fibrillation Screening Compared with Current Opportunistic Screening in Australian Primary Care: A Model-Based Economic Evaluation.","authors":"Ureni Halahakone, Sameera Senanayake, Victoria McCreanor, William Parsonage, David Brain","doi":"10.1007/s40258-026-01073-z","DOIUrl":"https://doi.org/10.1007/s40258-026-01073-z","url":null,"abstract":"<p><strong>Background: </strong>Although the guidelines recommend opportunistic screening for adults ≥ 65 years, screening for atrial fibrillation (AF) remains underutilised in Australia. The absence of guidance on how often to screen has resulted in variable practice and missed opportunities for AF detection. Previous studies have focused on handheld devices rather than 12-lead electrocardiogram (ECG) devices that are readily available in primary-care settings, and the evidence supporting an annual AF screening programme in Australia is limited. Therefore, the aim of this study is to compare the cost-effectiveness of an annual, structured, higher‑coverage opportunistic ECG screening approach (annual screening) with current unstructured opportunistic screening (current screening) in older adults in Australia.</p><p><strong>Methods: </strong>A Markov model was developed to evaluate two strategies for adults ≥ 65 years: (1) annual screening using 12-lead ECG and (2) current opportunistic screening. The model included 11 health states capturing AF treatment and outcomes, and simulations were run using monthly cycles. A health system perspective and 10-year time horizon were applied. To account for uncertainty, a probabilistic sensitivity analysis with 1000 iterations was undertaken and the results were assessed against a cost-effectiveness threshold of 28,000 Australian dollars (AU$) per quality-adjusted life year (QALY). Uncertainty was further examined through cost-effectiveness acceptability curves and scenario analyses to test the stability of findings under alternative assumptions.</p><p><strong>Results: </strong>Annual screening increased costs by AU$4213 and gained 0.43 QALYs, yielding an incremental cost-effectiveness ratio of AU$9797 per QALY gained. Probabilistic sensitivity analysis demonstrated that 100% of simulations yielded a positive incremental net monetary benefit. Scenario analyses demonstrated that both higher screening costs and less frequent 3-yearly screening were cost-effective in comparison to the current opportunistic screening, with incremental cost-effectiveness ratios below the cost-effectiveness threshold and positive incremental net monetary benefits in all scenarios.</p><p><strong>Conclusion: </strong>A structured annual screening approach for AF is likely to be a cost-effective strategy within the Australian primary-care setting. These findings highlight the benefits of more consistent screening practices for early AF detection and stroke prevention.</p>","PeriodicalId":8065,"journal":{"name":"Applied Health Economics and Health Policy","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149147606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}